Mattias Ivarsson is committed to fighting a nasty bacterium at the root of many hospital-acquired infections. This article describes the story behind Inositec’s technology and CEO.
10th November 2014
Categories
Most Recent
- Discovery work on Clostridium difficile toxin inhibitors published
- Inositec’s INS-3001 Significantly Reduces Vascular Calcification Data Presented at Kidney Week 2018 Indicates
- Inositec AG Appoints Dr Frits van Alphen as Chief Medical Officer
- Inositec wins Swiss Technology Award 2017
- Inositec featured in BioCentury